Colgate-Palmolive Company CL SPX
Company Overview
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under the Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline, and Suavitel brands to a range of traditional and eCommerce retailers, wholesalers, and distributors, as well as dentists and skin health professionals. It also offers pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand; and a fresh pet food sold to pet specialty and other retailers in Australia under Prime100 brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
Why Investors Should Care
Return on capital employed stands at 34.9%.
Operating margin of 20.9% supports profitability.
Offers a dividend yield of 2.37%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $20.38B (+1.4% YoY); net profit $2.13B.
- Trailing 12 Months Year-on-year growth — revenue +8.4%, earnings -5.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.2%, profit CAGR 1.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.19% |
| 1 Year: | 8.40% |
Compounded Profit Growth
| 5 Years: | 1.14% |
| 1 Year: | -5.90% |
Stock Price Performance
| 1 Year: | +5.04% |
| 6 Months: | +13.10% |
| 3 Months: | +9.07% |
| 1 Month: | +1.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.29 · Neutral
P/E of 35.28 is above the sector median of 20.95 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 34.9%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CL Colgate-Palmolive Company SPX | 91.03 | 35.28 | $72.84B | 2.37% | 34.88% | - | 2.19% | 1.14% |
| 2 | WMT Walmart Inc. SPX | 113.70 | 40.04 | $904.83B | 0.89% | 18.21% | 24.13% | 5.27% | 23.30% |
| 3 | COST Costco Wholesale Corporation NDXSPX | 921.75 | 46.46 | $408.78B | 0.60% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPX | 83.08 | 26.13 | $357.45B | 2.57% | 16.47% | 43.37% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPX | 146.08 | 21.36 | $340.16B | 2.85% | 22.93% | 31.11% | 0.36% | 1.66% |
| 6 | PM Philip Morris International Inc. SPX | 175.95 | 24.78 | $274.23B | 3.19% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPX | 135.45 | 21.23 | $185.13B | 4.10% | 15.41% | 43.88% | 4.93% | 2.11% |
| 8 | MO Altria Group, Inc. SPX | 70.16 | 14.65 | $117.16B | 5.89% | 38.27% | - | 1.24% | -1.89% |
| 9 | MNST Monster Beverage Corporation NDXSPX | 98.00 | 47.34 | $95.84B | 0.00% | 28.33% | 26.65% | 13.03% | 14.82% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 3.76B | 3.83B | 3.97B | 3.89B | 4.00B | 3.89B | 3.85B | 3.81B | 3.88B | 3.87B | 3.93B | 4.01B | 4.10B | 3.90B | 4.15B | 4.32B | 4.34B | 4.26B | 4.41B | 4.40B | 4.48B | 4.46B | 4.77B | 4.82B | 4.92B | 5.07B | 5.06B | 5.03B | 4.91B | 5.11B | 5.13B | 5.32B |
| Gross Profit | 2.39B | 2.37B | 2.35B | 2.29B | 2.25B | 2.30B | 2.32B | 2.25B | 2.27B | 2.30B | 2.38B | 2.33B | 2.41B | 2.30B | 2.27B | 2.25B | 2.29B | 2.31B | 2.32B | 2.41B | 2.46B | 2.37B | 2.54B | 2.64B | 2.64B | 2.56B | 2.62B | 2.57B | 2.55B | 2.55B | 2.71B | 2.79B | 2.88B | 3.04B | 3.07B | 3.07B | 2.99B | 3.07B | 3.05B | 3.23B |
| Operating Income | 860.00M | 932.00M | 1.14B | - | 867.00M | 944.00M | 1.07B | - | 912.00M | 878.00M | 957.00M | - | 983.00M | 946.00M | 874.00M | - | 879.00M | 888.00M | 856.00M | - | 952.00M | 946.00M | 1.02B | - | 1.00B | 996.00M | 967.00M | 860.00M | 884.00M | 947.00M | 909.00M | 974.00M | 1.03B | 1.05B | 1.09B | 1.06B | 1.08B | 1.08B | 1.06B | 964.00M |
| Net Income | 542.00M | 574.00M | 726.00M | -458.00M | 533.00M | 600.00M | 702.00M | 606.00M | 570.00M | 524.00M | 607.00M | 323.00M | 634.00M | 637.00M | 523.00M | 606.00M | 560.00M | 586.00M | 578.00M | 643.00M | 715.00M | 635.00M | 698.00M | 647.00M | 681.00M | 703.00M | 634.00M | 559.00M | 603.00M | 618.00M | 372.00M | 502.00M | 708.00M | 683.00M | 731.00M | 737.00M | 690.00M | 743.00M | 735.00M | 646.00M |
| Diluted EPS | 0.59 | 0.63 | 0.80 | -0.51 | 0.59 | 0.67 | 0.78 | 0.68 | 0.64 | 0.59 | 0.68 | 0.37 | 0.72 | 0.73 | 0.60 | 0.70 | 0.65 | 0.68 | 0.67 | 0.75 | 0.83 | 0.74 | 0.81 | 0.75 | 0.80 | 0.83 | 0.75 | 0.66 | 0.72 | 0.74 | 0.45 | 0.60 | 0.86 | 0.83 | 0.89 | 0.90 | 0.85 | 0.91 | 0.91 | 0.80 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.79B | 15.33B | 15.33B | 15.56B | 16.73B | 17.09B | 17.42B | 17.28B | 16.03B | 15.20B | 15.45B | 15.54B | 15.69B | 16.47B | 17.42B | 17.97B | 19.46B | 20.10B | 20.38B |
| Gross Profit | 7.75B | 8.63B | 9.01B | 9.20B | 9.59B | 9.93B | 10.20B | 10.11B | 9.40B | 9.12B | 9.28B | 9.23B | 9.32B | 10.02B | 10.38B | 10.25B | 11.33B | 12.16B | 12.25B |
| Operating Income | 2.72B | 3.10B | 3.62B | 3.49B | 3.84B | 3.89B | 3.56B | 3.56B | 2.79B | 3.96B | 3.71B | 3.69B | 3.55B | 3.88B | 3.33B | 2.89B | 3.98B | 4.27B | 3.31B |
| Net Income | 1.74B | 1.96B | 2.29B | 2.20B | 2.43B | 2.47B | 2.24B | 2.18B | 1.38B | 2.44B | 2.02B | 2.40B | 2.37B | 2.69B | 2.17B | 1.78B | 2.30B | 2.89B | 2.13B |
| Diluted EPS | 3.20 | 3.66 | 4.37 | 4.31 | 2.47 | 2.57 | 2.38 | 2.36 | 1.52 | 2.72 | 2.28 | 2.75 | 2.75 | 3.14 | 2.55 | 2.13 | 2.77 | 3.51 | 2.63 |
| R&D Expense | - | 240.00M | 256.00M | 256.00M | 262.00M | 259.00M | 267.00M | 277.00M | 274.00M | 289.00M | 285.00M | 277.00M | 281.00M | 290.00M | 307.00M | 320.00M | 343.00M | 355.00M | 366.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 9.98B | 11.13B | 11.17B | 12.72B | 13.39B | 13.98B | 13.44B | 11.94B | 12.12B | 12.68B | 12.16B | 15.03B | 15.92B | 15.04B | 15.73B | 16.39B | 16.05B | 16.33B |
| Total Equity | - | - | 1.92B | 3.12B | 2.67B | 2.38B | 2.19B | 2.31B | 1.15B | -299.00M | -243.00M | -60.00M | -102.00M | 117.00M | 743.00M | 609.00M | 401.00M | 609.00M | 212.00M | 54.00M |
| Cash & Equivalents | 490.00M | 429.00M | 555.00M | 600.00M | 490.00M | 878.00M | 884.00M | 962.00M | 1.09B | 970.00M | 1.31B | 1.53B | 726.00M | 883.00M | 888.00M | 832.00M | 775.00M | 966.00M | 1.10B | 1.29B |
| Long Term Debt | - | - | - | 3.15B | 2.81B | 4.43B | 4.93B | 4.75B | 5.64B | 6.25B | 6.52B | 6.57B | 6.35B | 7.33B | 7.33B | 7.19B | 8.74B | 8.22B | 7.29B | 6.87B |
| Total Liabilities | - | - | 7.93B | 7.88B | 8.36B | 10.18B | 11.00B | 11.45B | 12.07B | 11.98B | 12.11B | 12.43B | 11.96B | 14.48B | 14.82B | 14.07B | 14.93B | 15.44B | 15.50B | 15.96B |
| Current Liabilities | - | - | 2.95B | 3.60B | 3.73B | 3.72B | 3.74B | 4.58B | 3.95B | 3.53B | 3.31B | 3.41B | 3.34B | 4.04B | 4.40B | 4.05B | 4.00B | 4.74B | 5.76B | 6.85B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.25B | 2.30B | 3.28B | 3.21B | 2.90B | 3.20B | 3.20B | 3.30B | 2.95B | 3.14B | 3.05B | 3.06B | 3.13B | 3.72B | 3.33B | 2.56B | 3.75B | 4.11B | 4.20B |
| Investing Cash Flow | -528.00M | -613.00M | -841.00M | -658.00M | -1.21B | -865.00M | -890.00M | -859.00M | -685.00M | -499.00M | -471.00M | -1.17B | -2.10B | -779.00M | -592.00M | -1.60B | -742.00M | -534.00M | -817.00M |
| Financing Cash Flow | -1.80B | -1.53B | -2.27B | -2.62B | -1.24B | -2.30B | -2.14B | -2.17B | -2.28B | -2.23B | -2.45B | -2.68B | -870.00M | -2.92B | -2.77B | -952.00M | -2.79B | -3.39B | -3.26B |
| Capital Expenditure | - | - | - | - | -537.00M | -565.00M | -670.00M | -757.00M | -691.00M | -593.00M | -553.00M | -436.00M | -335.00M | -409.00M | -567.00M | -696.00M | - | - | - |
| Free Cash Flow | - | - | - | - | 2.36B | 2.63B | 2.53B | 2.54B | 2.26B | 2.55B | 2.50B | 2.62B | 2.80B | 3.31B | 2.76B | 1.86B | - | - | - |
| Share Buybacks | 1.27B | 1.07B | 1.06B | 2.02B | 1.81B | 1.94B | 1.52B | 1.53B | 1.55B | 1.33B | 1.40B | 1.24B | 1.20B | 1.48B | 1.32B | 1.31B | 1.13B | 1.74B | 1.21B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 56.2% | 56.3% | 58.8% | 59.1% | 57.3% | 58.1% | 58.6% | 58.5% | 58.6% | 60.0% | 60.0% | 59.4% | 59.4% | 60.8% | 59.6% | 57.0% | 58.2% | 60.5% | 60.1% |
| Operating Margin % | 19.7% | 20.2% | 23.6% | 22.4% | 23.0% | 22.8% | 20.4% | 20.6% | 17.4% | 26.0% | 24.0% | 23.8% | 22.6% | 23.6% | 19.1% | 16.1% | 20.5% | 21.2% | 16.2% |
| Net Margin % | 12.6% | 12.8% | 14.9% | 14.2% | 14.5% | 14.5% | 12.9% | 12.6% | 8.6% | 16.1% | 13.1% | 15.4% | 15.1% | 16.4% | 12.4% | 9.9% | 11.8% | 14.4% | 10.5% |
| ROE % | - | 101.8% | 73.5% | 82.4% | 102.4% | 112.9% | 97.2% | 190.4% | -462.9% | -1,004.5% | -3,373.3% | -2,352.9% | 2,023.1% | 362.7% | 355.7% | 445.1% | 377.7% | 1,362.7% | 3,948.1% |
| ROCE % | - | 44.1% | 48.0% | 46.9% | 42.6% | 40.3% | 37.8% | 37.5% | 33.2% | 44.9% | 40.0% | 41.9% | 32.3% | 33.7% | 30.3% | 24.7% | 34.2% | 41.5% | 34.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.08% | 72.64M | $6.71B |
| 2 | Vanguard Capital Management LLC | 6.53% | 52.22M | $4.82B |
| 3 | State Street Corporation | 5.96% | 47.72M | $4.41B |
| 4 | Price (T.Rowe) Associates Inc | 4.22% | 33.73M | $3.12B |
| 5 | Vanguard Portfolio Management LLC | 2.98% | 23.82M | $2.20B |
| 6 | Geode Capital Management, LLC | 2.86% | 22.90M | $2.12B |
| 7 | Morgan Stanley | 2.61% | 20.88M | $1.93B |
| 8 | Bank Of New York Mellon Corporation | 1.56% | 12.52M | $1.16B |
| 9 | Deutsche Bank AG | 1.49% | 11.93M | $1.10B |
| 10 | Goldman Sachs Group Inc | 1.18% | 9.48M | $875.47M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CL
Colgate-Palmolive (CL) Stock Looks Rich Relative To Its Earnings Valuation - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPMGRpTXJPNkxnWHowTUZPbTFOM2VxUlVzc3BieE9QdDhodzFVaTlpRUZ6aFQ3dUNRY0RhdThlWmxyek5DUHkzdjVSd2MtcXNZdmdmMWVuY1VTQVdzcmNGaWk3bGxFaHViUWp0UEVPNHdRY3VhSGRaaUVhcG5ITDZNTDg2dkFOZXhrMjVkUH…
Universal Health Services Inc. Cl B stock outperforms competitors despite losses on the day - MarketWatch
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNRzhMTGgtQWItTUs3dVRVYnlvRmNZMlFJWjFEX3MyMmJ0TkFfWlNFX1ltMHRXRThMWWNvcE5zamlZTkljbTlGMkVuTWM4M0FZQi05OUpNTllNczFTczduaGc4QUZBVFNVdl9LbkdiLXBVZG10T1lDcERxNG1zX1oxN2haNzlPX2kyYlFQcE…
The Bull Case For Colgate-Palmolive (CL) Could Change Following Margin Strength But Slower Organic Growth - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQY3lSbmVGd2hmeGxTc2tqd05relF3QzlRTFptSFhzcVJTNzZhcmhDd081Uk41WTVibGJ1TjJyeWZ6OGhFalVwaWt1OHdwNDZ1MnVxZmtYR2JRRVppdEZsaUJLNzlROFJQamhJYUJhQ0lIT0pqdVdBYThheFZLQmowbzMzdTJPN3Q4S1pMeV…
CL Maintained by Citigroup -- Price Target Raised to $110 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQYmN3ZVRucjQzWFdXVmxSWWFrQ0w2UFd3aUk5dTRqaGZWSEpVRTBkWG5MYVp3UW5EeWwxS0pwU2Vfd0FDaDNvT0dVZ1BaSXVHRUppSFNDQ240RC12NWZyX29ZUUVzeDZPMFgwZl9hakRMVThjUTByYmVlelpzS0JWd28yMkRQejVMcndRbW…
Calamos Advisors LLC Has $25.90 Million Stock Holdings in Colgate-Palmolive Company $CL - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxQYUhXbktjZGpNMkhsZmFSUkpZd0w2VWZZd0xCejgxT3h6MTd5YW9SMF9YREQ5Y1Bma1Z5V2FSOHdkOU5naHVGek9weXJqd2JvUkFnWGdRU0ZfWjV3S0ZaXzNwSzVnejBKaUljV0IwLUQ2SW5oNUlFMDJENC0xRkJxQnlQeGlwcTYtb2sxR3…
Fox Corp. Cl B stock underperforms Tuesday when compared to competitors - MarketWatch
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPOUoxS2V6OGlySVF1bHVnOHpIQzlrS203Ty1pd2RabVVWOS02OGs0cHN3SmRDZjJrNjdpNFluZ010eEdqemNtNVVNdmxBNklTUmUtV0QwWHhkYXB5dzAzcnRmS2ZjYlE2bTYxaWtaYmd1NGQwQk1JZDFzMjVFajJaS2E3ZGc1MkdvUzBjMk…
CL — Frequently Asked Questions
What is the current share price of Colgate-Palmolive Company (CL)?
As of 2026-07-14 21:23 PDT, Colgate-Palmolive Company (CL) trades at $91.03 on NYSE. Its 52-week range is $74.06 to $98.53.
What is the market capitalisation of CL?
Colgate-Palmolive Company (CL) has a market capitalisation of $72.84B on NYSE.
What is the P/E ratio of CL?
CL trades at a trailing price-to-earnings (P/E) ratio of 35.28. The industry average P/E is 20.95. Its price-to-book (P/B) ratio is 494.20.
Does CL pay a dividend?
Colgate-Palmolive Company (CL) currently offers a dividend yield of 2.37%.
Is CL a good stock to buy?
This page provides a data-driven analysis of Colgate-Palmolive Company (CL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.